Roth Capital Has Negative Outlook for PolyPid Q3 Earnings

PolyPid Ltd. (NASDAQ:PYPD) – Equities research analysts at Roth Capital decreased their Q3 2025 earnings estimates for shares of PolyPid in a research note issued on Wednesday, August 13th. Roth Capital analyst B. Pachaiyappan now forecasts that the company will post earnings per share of ($0.69) for the quarter, down from their prior forecast of ($0.35). Roth Capital has a “Buy” rating on the stock. The consensus estimate for PolyPid’s current full-year earnings is ($1.79) per share. Roth Capital also issued estimates for PolyPid’s Q4 2025 earnings at ($0.64) EPS, FY2025 earnings at ($2.81) EPS, Q1 2026 earnings at ($0.41) EPS, Q2 2026 earnings at ($0.42) EPS, Q3 2026 earnings at ($0.45) EPS, Q4 2026 earnings at ($0.44) EPS and FY2026 earnings at ($1.73) EPS.

PYPD has been the topic of a number of other research reports. Craig Hallum reaffirmed a “buy” rating and set a $13.00 target price (down previously from $15.00) on shares of PolyPid in a research note on Thursday. HC Wainwright reaffirmed a “buy” rating and set a $13.00 target price on shares of PolyPid in a research note on Wednesday, August 13th. Wall Street Zen lowered shares of PolyPid from a “hold” rating to a “sell” rating in a research note on Saturday. Finally, JMP Securities cut their target price on shares of PolyPid from $16.00 to $14.00 and set a “market outperform” rating on the stock in a research note on Tuesday, June 17th. One analyst has rated the stock with a sell rating, five have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $12.40.

PolyPid Trading Up 0.6%

Shares of PYPD opened at $3.45 on Monday. The firm’s 50-day moving average price is $3.50 and its 200-day moving average price is $3.06. The firm has a market capitalization of $54.86 million, a price-to-earnings ratio of -0.90 and a beta of 1.40. PolyPid has a 1-year low of $2.30 and a 1-year high of $3.93.

PolyPid (NASDAQ:PYPD) last announced its quarterly earnings results on Wednesday, August 13th. The company reported ($0.78) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.25).

Institutional Inflows and Outflows

A number of large investors have recently bought and sold shares of the business. AIGH Capital Management LLC lifted its position in PolyPid by 27.0% during the 2nd quarter. AIGH Capital Management LLC now owns 1,194,108 shares of the company’s stock valued at $4,215,000 after acquiring an additional 253,727 shares during the period. J. Goldman & Co LP purchased a new position in PolyPid during the 4th quarter valued at about $391,000. Finally, Lumbard & Kellner LLC purchased a new position in PolyPid during the 2nd quarter valued at about $135,000. 26.47% of the stock is owned by hedge funds and other institutional investors.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions.